Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AISTCM: TCM for Acute Ischemic Stroke
NCT00351806Phase 4
Key facts
- Status
- Completed
- Start
- Jul 2005
- Countries
- 1
- Sponsor
- Guangzhou University of Chinese Medicine
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Drugs
- erigeron breviscapusHuatuo ZaizaoCompound Stroke Herbal Medicine
- Conditions
- ischemic stroke
01
Overview
Phase 4, randomised, single-blind trial of erigeron breviscapus, Huatuo Zaizao and Compound Stroke Herbal Medicine in ischemic stroke (2 arms), sponsored by Guangzhou University of Chinese Medicine. Primary endpoints: Death Rate and Barthel Index. Started Jul 2005; status: completed.
02
Design
2 arms- Study design
- RandomizedSingle-blind
Chinese herbal medicine
Erigeron breviscapus injection + Hua Tuo Zai Zao Wan + Compound stroke herbal medicine
Placebo
Placebo comparator
03
Endpoints
Primary
Death Rate
Barthel Index
Secondary
Glasgow Outcome Scale
Modified Rankin Scale
National Institute of Health Stroke Scale
Stroke Specific Quality of Life
Scale of Traditional Chinese Medicine
Beyond the preview
Go deeper on NCT00351806.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00351806.